Showing results (211-220 of 330) with videos related to
Sort By:
Pageof 33
Nature Communications|February 27, 2016
RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancerNyam-Osor Chimge, Gillian H Little, Sanjeev K Baniwal, et al.Cancer Research|April 18, 2023
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast CancerXuxu Gou, Beom-Jun Kim, Meenakshi Anurag, et al.Cancer Chemotherapy and Pharmacology|April 17, 2008
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignanciesPaula M Fracasso, Joel Picus, Jonathan D Wildi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasHoward A Burris, Herbert I Hurwitz, E Claire Dees, et al.Transplantation Direct|October 13, 2023
Real-world Experiences in the Transplantation of Hepatitis C-NAAT-positive OrgansJulie M Steinbrink, Jennifer Byrns, Carl Berg, et al.Molecular Endocrinology (Baltimore, Md.)|August 23, 2014
Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomicsMohan Liu, Paul E Goss, James N Ingle, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast CancerXian Wang, Jamunarani Veeraraghavan, Chia-Chia Liu, et al.World Journal of Surgery|January 24, 2021
Definition and Analysis of Textbook Outcome: A Novel Quality Measure in Kidney TransplantationSamantha E Halpern, Dimitrios Moris, Brian I Shaw, et al.The New England Journal of Medicine|October 12, 2007
HER2 and response to paclitaxel in node-positive breast cancerDaniel F Hayes, Ann D Thor, Lynn G Dressler, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2015
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Michael Naughton, et al.Pageof 33